3rd April 2026
As new variants of SARS-CoV-2 continue to emerge, each one brings a familiar cycle of concern, headlines, and uncertainty. The latest to attract attention is the BA.3.2 subvariant—nicknamed "Cicada." Reports of its spread in the United States and beyond have raised an obvious question: is this something the UK should be worried about?.
At present, the answer is reassuring—but not dismissive.
A Variant on the Radar, Not Yet Dominant
The "Cicada" variant has been detected in the UK, but it is not currently driving a major wave of infections. Compared to dominant strains, it represents only a small fraction of cases. Health authorities are monitoring it closely, as they do with all emerging variants, but there is no sign that it has taken hold in a way that would significantly alter the trajectory of infections across the country.
Globally, the picture is more mixed. The variant has gained more ground in the United States and has been identified in multiple countries. In some regions, it has grown to a noticeable share of cases, suggesting it has a competitive advantage in transmission—but not necessarily in severity.
Familiar Illness, Not a More Dangerous Virus
Crucially, early evidence indicates that BA.3.2 is not more dangerous than previous recent variants, particularly those in the Omicron family.
This is an important distinction. Earlier in the pandemic, variants such as Alpha and Delta were associated with clear increases in severity and hospitalisation risk. By contrast, newer Omicron-lineage variants—including this one—tend to cause milder disease on average, especially in populations with existing immunity from vaccines or prior infections.
Symptoms linked to the “Cicada” variant remain familiar: sore throat, cough, fatigue, and fever. For most people, the illness resembles a heavy cold or flu-like infection, rather than the severe respiratory disease seen in earlier waves.
Why Scientists Are Still Paying Attention
Despite the relatively mild profile, there are reasons why BA.3.2 is being watched closely.
The variant carries a large number of mutations, particularly in the spike protein—the part of the virus that allows it to enter human cells. These mutations raise the possibility of immune escape, meaning the virus may partially evade protection from previous infections or vaccinations.
In practical terms, this doesn't necessarily make people sicker, but it could make reinfections more common or allow the variant to spread more easily through populations that already have some immunity.
This is now a defining feature of the pandemic's later stages: not waves driven by dramatically more dangerous variants, but by incremental evolutionary changes that help the virus persist.
The Bigger Picture: Living With a Changing Virus
The emergence of the “Cicada” variant highlights how the pandemic has shifted. The key concern is no longer whether a variant will dramatically increase severity, but whether it will:
Spread more efficiently
Partially bypass immunity
Place renewed pressure on health systems
So far, BA.3.2 does not appear to do these things to a degree that would fundamentally change the situation in the UK.
Conclusion: Caution Without Alarm
For now, the “Cicada” variant is best understood as another iteration of Omicron rather than a new phase of the pandemic.
It is present in the UK, but not widespread. It may spread more easily or cause reinfections, but there is no strong evidence that it leads to more severe illness. In a population with substantial immunity, its overall impact is likely to remain limited.
The appropriate response, then, is not alarm but awareness. The virus continues to evolve, but the balance has shifted: we are no longer facing a radically more dangerous threat with each new variant, but a gradually adapting one that we are increasingly equipped to handle.
And dare we say it again - Wash Your Hands.